OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Companyâs principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Companyâs technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Companyâs wholly owned subsidiary is OKYO Pharma US Inc.
More about the company